Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Opsens Inc T.OPS

OpSens Inc. is a medical device cardiology-focused company. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. The Company’s segments include Medical and Industrial. The Medical segment focuses on physiological measurements, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and also supplies a range of miniature optical sensors to measure pressure and temperature to be used in a range of applications that can be integrated into other medical devices. The Industrial segment develops, manufactures and installs fiber optic sensing solutions for critical and demanding industrial applications. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and lesions access. It is approved for sale in the United States, European Union, Japan and Canada.


TSX:OPS - Post by User

Comment by Possibleidiot01on Nov 22, 2022 2:57pm
148 Views
Post# 35119583

RE:RE:If I understand well...

RE:RE:If I understand well...Follow where the money went .

Operating expenses for FY 2022 were $28.8 million compared with $19.6 million for FY 2021. The increase in operating expenses is primarily due to increased headcount in sales and marketing, research and development, and administration in preparation for the Company's launch of the SavvyWire for which the Company received regulatory clearance in Canada and United States

$3.2 million for operating expenses
$0.6 million for foriegn exchange

                                            Q4/2022  2021 fY2022 FY2021

Sales and marketing

4,339

2,191

12,576

7,649

Research and development

2,244

1,340

8,358

5,510

 

 

 
 Seems to be in line with commercializing a product ; takes money to make money. Considering full scale release under way now in Canada and scheduled in U.S. later this year - sales should increase.
<< Previous
Bullboard Posts
Next >>